5月21日，ImmunityBio盘中上涨5.03%，报8.15美元/股，成交额1.8亿美元。
消息面上，公司近日密集释放多重利好：一是获得五项美国专利，覆盖其IL-15受体激动剂ANKTIVA联合BCG治疗癌症的组合产品、给药方案及商业化试剂盒，专利有效期至少延续至2035年；二是与日本BCG实验室签署独家协议，获得在美国开发及商业化Tokyo-172卡介苗的权利，该产品已有三期临床数据支持且在日本获批；三是在AUA 2026年会上公布ANKTIVA联合BCG相较于Nadofaragene及TAR-200在完全缓解率方面的积极疗效比较数据。上述进展显著强化了公司在膀胱癌免疫治疗领域的产品管线与商业化前景。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.